|
|
The Food and Drug Administration has announced that it will allow doctors to prescribe the irritable bowel syndrome drug Zelnorm to a limited number of patients for whom its benefits outweigh the risk of cardiovascular problems. The agency had asked the drug’s manufacturer, Novartis Pharmaceutical, to withdraw it from the market in March due to the potential risk of Zelnorm side effects.
Read more...
The Food and Drug Administration has announced that it will allow the irritable bowel syndrome drug Zelnorm to be prescribed to some patients under new tightened restrictions. Zelnorm was pulled from the market in March 2007 after several studies linked the drug to an increased risk of heart attack, stroke and chest pain.
Read more...
China’s State Food and Drug Administration has ordered domestic companies to stop manufacturing and selling the irritable bowel syndrome drug Zelnorm. The agency also warned patients to stop taking the drug because of the risk of Zelnorm side effects.
Read more...
According to a recent article in Forbes magazine, sales of the irritable bowel syndrome (IBS) drug Zelnorm increased by more than one-third thanks to a series of television advertisements promoting the drug. Zelnorm was recently withdrawn by its manufacturer, Novartis, after it was linked with an increased risk of heart attack, stroke and other cardiovascular side effects of Zelnorm. Officials from the Food and Drug Administration say that Novartis is planning to issue a Zelnorm recall, although no date has been announced.
Read more...
The manufacturer of the irritable bowel syndrome (IBS) drug Zelnorm has agreed to stop selling the medication at the request of the Food and Drug Administration. The decision to pull Zelnorm from the market came after a number of studies suggested that the drug could increase the risk of heart attack or stroke for patients.
Read more...
|
|
